Bispecific antibody · Immune activation, directed at mesothelin (MSLN) and CD3 (CD3E) · developed by Context Therapeutics
CT-95 is a bispecific T-cell engager antibody with two mesothelin-binding arms and two CD3-binding domains. It targets mesothelin on tumor cells and CD3 on cytotoxic T-lymphocytes, redirecting T-cells to kill mesothelin-expressing cancer cells. It is being studied in mesothelin-expressing tumors including ovarian cancer, mesothelioma, pancreatic cancer, and other solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06756035 | Phase 1 | Mesothelin-Expressing Tumors | Recruiting | CNTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cholangiocarcinoma AdvancedCholangiocarcinoma Non-resectableColorectal CancerEpithelial Ovarian CancerLung Adenocarcinoma MetastaticMalignant Peritoneal Mesothelioma, AdvancedMalignant Pleural Mesothelioma, AdvancedMesothelin-expressing Advanced CancersMesothelin-Expressing TumorsMesothelin-positive Advanced Malignant Solid TumorsPancreatic Adenocarcinoma Advanced or Metastatic
Updated Oct 3, 2026. Something wrong or missing? Report it on the CNTX page.
See CNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CNTX catalysts and pipeline →